X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs PANACEA BIOTECH - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES PANACEA BIOTECH PIRAMAL ENTERPRISES/
PANACEA BIOTECH
 
P/E (TTM) x 39.0 136.4 28.6% View Chart
P/BV x 3.2 3.0 107.0% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 PIRAMAL ENTERPRISES   PANACEA BIOTECH
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
PANACEA BIOTECH
Mar-14
PIRAMAL ENTERPRISES/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs2,095149 1,408.9%   
Low Rs1,02582 1,245.4%   
Sales per share (Unadj.) Rs492.884.1 585.7%  
Earnings per share (Unadj.) Rs72.6-18.3 -396.3%  
Cash flow per share (Unadj.) Rs94.7-6.7 -1,413.3%  
Dividends per share (Unadj.) Rs21.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs862.583.7 1,030.3%  
Shares outstanding (eoy) m172.5661.25 281.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.21.4 230.6%   
Avg P/E ratio x21.5-6.3 -340.8%  
P/CF ratio (eoy) x16.5-17.2 -95.6%  
Price / Book Value ratio x1.81.4 131.1%  
Dividend payout %28.90-   
Avg Mkt Cap Rs m269,1947,074 3,805.2%   
No. of employees `0004.02.8 145.9%   
Total wages/salary Rs m17,9391,449 1,237.8%   
Avg. sales/employee Rs Th21,190.31,874.1 1,130.7%   
Avg. wages/employee Rs Th4,470.1527.0 848.3%   
Avg. net profit/employee Rs Th3,120.0-407.7 -765.2%   
INCOME DATA
Net Sales Rs m85,0375,154 1,650.0%  
Other income Rs m2,338100 2,342.2%   
Total revenues Rs m87,3745,254 1,663.2%   
Gross profit Rs m34,991-766 -4,566.3%  
Depreciation Rs m3,817711 536.8%   
Interest Rs m20,3101,503 1,351.3%   
Profit before tax Rs m13,202-2,881 -458.3%   
Minority Interest Rs m1,69911 15,731.5%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m-1001,771 -5.6%   
Tax Rs m2,28117 13,578.6%   
Profit after tax Rs m12,520-1,121 -1,116.6%  
Gross profit margin %41.1-14.9 -276.7%  
Effective tax rate %17.3-0.6 -2,962.6%   
Net profit margin %14.7-21.8 -67.7%  
BALANCE SHEET DATA
Current assets Rs m87,5903,810 2,298.8%   
Current liabilities Rs m185,5788,365 2,218.4%   
Net working cap to sales %-115.2-88.4 130.4%  
Current ratio x0.50.5 103.6%  
Inventory Days Days31156 19.9%  
Debtors Days Days4867 70.7%  
Net fixed assets Rs m108,52314,480 749.5%   
Share capital Rs m34561 563.0%   
"Free" reserves Rs m148,481903 16,441.2%   
Net worth Rs m148,8265,127 2,902.7%   
Long term debt Rs m144,9575,832 2,485.7%   
Total assets Rs m482,39419,433 2,482.3%  
Interest coverage x1.7-0.9 -180.0%   
Debt to equity ratio x1.01.1 85.6%  
Sales to assets ratio x0.20.3 66.5%   
Return on assets %6.82.0 346.5%  
Return on equity %8.4-21.9 -38.5%  
Return on capital %12.03.6 328.7%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m15,0011,539 974.6%   
Fx outflow Rs m5,150942 546.7%   
Net fx Rs m9,851597 1,649.5%   
CASH FLOW
From Operations Rs m-100,393599 -16,754.5%  
From Investments Rs m-24,202-438 5,526.8%  
From Financial Activity Rs m135,705-303 -44,846.2%  
Net Cashflow Rs m11,110-141 -7,862.5%  

Share Holding

Indian Promoters % 52.9 74.5 71.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 0.6 666.7%  
FIIs % 26.6 1.3 2,046.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 23.6 69.9%  
Shareholders   93,274 10,259 909.2%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   STRIDES SHASUN LTD  ELDER PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; Realty Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a dull note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Jan 16, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS